Please assess the completion status of the following clinical trial:

Trial Title: A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, \>/= 18 years of age~* Participants with multiple basal cell carcinomas, including participants with Gorlin syndrome, with at least 6 clinically evident basal cell carcinomas at the time of randomization, of which 3 measure 5 mm or more in diameter and are considered target lesions. All other lesions are considered to be non-target lesions~* Histopathologic confirmation that at least one of the three target lesions is basal cell carcinoma~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~* Adequate renal and hepatic function and hematopoietic capacity~* Women of childbearing potential must agree to use contraception as defined by protocol during treatment and for at least 9 months after completion of study treatment~* Male participants with female partners of childbearing potential must agree to use contraception as defined by protocol during treatment and for 2 months after completion of study treatment~Exclusion Criteria:~* Inability or unwillingness to swallow capsules~* Pregnant or breastfeeding women~* Any metastatic basal cell carcinoma~* Locally advanced basal cell carcinoma lesion that is considered to be inoperable or to have medical contraindications to surgery~* Recent (i.e., within the past 28 days prior to randomization) or current participation in another experimental drug study~* Known or suspected alcohol abuse~* One of the following known rare hereditary conditions: galactose intolerance, primary hypolactasia or glucose-galactose malabsorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vismodegib Intermittent Schedule (Type: EXPERIMENTAL): Vismodegib intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo, repeated 3 times with a final course of vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
- Vismodegib Induction Followed by Intermittent Schedule (Type: EXPERIMENTAL): Vismodegib beginning with 24 weeks induction followed by intermittent schedule 8 weeks placebo, 8 weeks vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up

Based on this trial design, predict the completion outcome and termination type (if applicable).